Knoubis Bio Inc

Non-immunosuppressive Rheumatoid Arthritis Dmard - Abstract This Proposal Is Focused on Development of a Novel Non-immunosuppressive Biologic Therapy for Ra by Targeting Fibroblast-like Synoviocytes, Local Joint-lining Cells That Substantially Contribute to Joint Destruction During Rheumatoid Arthritis (ra). the Development of Immunosuppressant Disease-modifying Anti-rheumatic Agents (DMARDS) Has Dramatically Improved the Quality of Life of Ra Patients; However a Large Proportion of Patients Still Fail to Reach Sufficient Control of Disease Activity on the Currently Available Ra Medications. There Is a Need for Novel Non-immunosuppressive Therapies for Ra That Can Be Used Alone or in Combination With Current Dmards. to Address This Need, We Are Seeking to Target Fibroblast-like Synoviocytes as a Non- Immunosuppressive Option for Ra. Here, We Will Demonstrate Our Biologic Reduces FLS Migration and Invasion and Reverses Arthritis in Mice. This Project Addresses a Major Unmet Medical Need in Ra, the Lack of Non- Immunosuppressive Therapies for Controlling Disease Activity. Once We Obtain Proof-of-concept Data During This Phase I Project, We Will Apply for Phase Ii Funding to Further Develop the Lead and Characterize Its Preclinical Efficacy and Safety.